Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
Status:
Not yet recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will
be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that
receive 6 bimonthly intravitreal bevacizumab, and control group (50 eyes) that undergo
regular follow-up for Diabetic Retinopathy. Diabetic macular edema (DME) will be treated
independently in all groups by intravitreal bevacizumab. Primary outcome will be the
percentage of patients with progression of 2 or more stages through international diabetic
retinopathy staging. The secondary measures will be changes in best corrected visual acuity
(BCVA) and central macular thickness (CMT), and number of examinations and injection.